Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Jul 24, 2021 11:39pm
151 Views
Post# 33601585

RE:RE:RE:Additional thoughts on the ATM

RE:RE:RE:Additional thoughts on the ATMAt first I thought the ATM had to be the result of a positive development or strategy to strengthen their position in in way that will prove additional shareholders value. Now it just looks like the potential for further dilution. If they don't make an announcement by Monday morning and clarify the intent, I'm cutting my losses and significantly reducing my position. I don't understand how you can file something like this without the prospectus. I don't understand how a press release gets released and not immediately inform your shareholders and the market what's going on. I don't like the shiftiness in the strategy that has occurred and the continued surprises. It would be different if the surprises were positive, but they've only ever been negative since I've been invested the last few years. I had super high hopes for this stock thanks to all of your amazing research and communication. I do feel like management has lied or at least misled us at various points. Maybe that's not completely fair, but the other answer is that they aren't able to fully visualize the right approach and have to keep repositioning, in which case management would be considered incompetent for the task at hand. I don't want to be invested in something I cannot trust. I get that things change quickly and sometimes management has to adapt strategies that they cannot always fully disclose. However, there have been too many switcheroos in my opinion. I was invested in a different stock with similar issues and after 5 years, the market still wouldn't forgive it and it lags it's peers today in spite of many impressive accomplishments. This whole tight lipped thing from management has me questioning their agenda and asking why all too often. It doesn't feel right. I hope I'm wrong.
<< Previous
Bullboard Posts
Next >>